Nuvalent Inc (NUVL)
65.62
-0.86
(-1.29%)
USD |
NASDAQ |
May 31, 16:00
65.57
-0.05
(-0.08%)
After-Hours: 20:00
Nuvalent Cash from Operations (Quarterly): -36.09M for March 31, 2024
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -36.09M |
| December 31, 2023 | -30.21M |
| September 30, 2023 | -22.98M |
| June 30, 2023 | -22.14M |
| March 31, 2023 | -24.41M |
| December 31, 2022 | -17.78M |
| September 30, 2022 | -18.18M |
| June 30, 2022 | -15.48M |
| March 31, 2022 | -13.54M |
| Date | Value |
|---|---|
| December 31, 2021 | -12.96M |
| September 30, 2021 | -11.40M |
| June 30, 2021 | -9.712M |
| March 31, 2021 | -5.933M |
| December 31, 2020 | -4.937M |
| September 30, 2020 | -4.071M |
| June 30, 2020 | -2.946M |
| March 31, 2020 | -2.995M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
-36.09M
Minimum
Mar 2024
-2.946M
Maximum
Jun 2020
-15.04M
Average
-13.54M
Median
Mar 2022
Cash from Operations (Quarterly) Benchmarks
| Geron Corp | -62.25M |
| Verastem Inc | -28.31M |
| Karyopharm Therapeutics Inc | -43.72M |
| Syndax Pharmaceuticals Inc | -83.55M |
| Arvinas Inc | -97.50M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -206.77M |
| Cash from Financing (Quarterly) | 5.986M |
| Free Cash Flow | -111.41M |
| Free Cash Flow Per Share (Quarterly) | -0.5625 |
| Free Cash Flow Yield | -2.83% |